secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-07-13T23:59:59+00:00
Accession:  0001193125-22-192874
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX cuts ~40% of staff, $10M restructuring charge; COO, CFO, CMO to depart
-----------------------------------------------------------------------------

- Workforce reduction of ~40% primarily in development and G&A; completion expected by Q4 2022.
- Estimated restructuring charges of ~$10M, mainly severance, recorded in Q3 and Q4 2022.
- Cash runway extended into 2025 as a result of the restructuring.
- President/COO Amy Peterson to leave effective Sept 12, 2022; CFO Carlos Campoy and CMO Alison Hannah effective Sept 30, 2022.
- Company to prioritize pre-clinical/early clinical pipeline with two INDs planned for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/0001193125-22-192874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522192874/d267419d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-192874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer